Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Dermatologic 10CNS 9Genitourinary 7Breast 7Thoracic 5Gynecologic 5Lymphoid 4Myeloid 3Sarcoma 2Other hematologic neoplasm 2Tumor-Agnostic 1Plasma cell 1Head & Neck 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Anemia, Refractory 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 8Cyclosporine 8Cyclophosphamide 7Tacrolimus 5Filgrastim 5Cytarabine 5Carboplatin 4Azacitidine 4olaparib 3Thiotepa 3Lenalidomide 3Etoposide 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3venetoclax 2tipifarnib 2sargramostim 2peginesatide 2laromustine 2hematide 2enasidenib 2alvocidib 2aldesleukin 2Vorinostat 2Tretinoin 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × poly ICLC × Classical hematology × Clear all
NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
8 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡